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Figure 7

Fibrinogen Family Tree
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FIGURE 8

PURIFICATION SCHEME
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FIGURE 9

Western Blot (under non-reducing conditions)
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FIGURE 10

Western Blot (SDS-PAGE under Reducing Conditions)

Lane

Sample

1.
2.

human Fibrinogen (100 ngs)

3.
4.
5.

6.
7.
8.

hFib (50 ngs)
hFib (1 Ongs)
Mouse Plasma Derivative (200 ngs)

TG whey (pellet-2) 60 ngs
TG whey (pellet-2) 30 ngs
TG whey (pellet-2) 15 ngs
TG whey (pellet-2) 8 ngs

U.S. Patent

Oct. 14, 2008

Sheet 11 of 11

US 7.435,869 B2

FIGURE 11

Analysis of products under reducing conditions
Thrombin assisted clot formation
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These highly complex characteristics of the functional FIB
molecule has made unpredictable and difficult the expression,
assembly and secretion of fully formed and functional recom
binant molecules. A cDNA encoding the human FIBAC.
chain has been expressed in bacteria. Lord, DNA 4:33 (1985).
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Cross-Reference To Related Applications

This is of limited usefulness, however, since the other fibrino

This application is a divisional of U.S. Ser. No. 08/443,184,
filed on May 17, 1995, now U.S. Pat. No. 6,984,772, which is
a continuation-in-part of U.S. Ser. No. 08/198,068, filed on
Feb. 18, 1994, now abandoned, each of which are incorpo
rated herein by reference in their entirety.
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BACKGROUND OF THE INVENTION

The present invention relates in general to the use of trans
genic animals to produce therapeutically useful amounts of
clinically important recombinant proteins. More particularly,
this invention relates to the production in transgenic animals
of clinically useful quantities of the blood clotting protein,
fibrinogen (“FIB’).
The ultimate event in the blood clotting cascade is the
thrombin-catalyzed conversion of FIB (Mr 340,000) to
fibrin (Mr 329,000), the latter forming the fibrin clot. FIB
deficiency is generally transmitted as an autosomal recessive
trait and may manifest as a complete or partial absence of FIB
from the blood plasma. Clinically, the disease resembles
moderate or mild hemophilia. Congenital fibrinogen abnor
mality may be due to the hereditary synthesis of structurally
or functionally abnormal molecules, as in Vlissingen,
Ijmuiden and Nijmegen fibrinogens. An acquired deficiency
of this protein may occur due to impaired hepatic synthesis of
the protein, as occurs, for example, in hepatitis or hepatic
necrosis, or to accelerated destruction of the protein caused,
for example, by increased blood proteolytic activity.
Control of bleeding in such patients is currently achieved
by transfusion of FIB contained in freshly-frozen human
plasma or in concentrates of the protein isolated from donor
blood. While these replacement therapies are generally effec
tive, they place patients at risk for virus-transmissible dis
eases such as hepatitis or AIDS. Although this risk has been
greatly reduced by inactivating such viruses with heat or
organic solvents, such preparations have greatly increased the

15

addition, there are serious drawbacks to the use of mamma
25

30

35

lian cell tissue culture systems for production of FIB. These
include the high costs of growth media, the labor intensive
nature of such systems, and limited production capacity.
An important need persists for an efficient and relatively
inexpensive means of producing clinically useful amounts of
infectious particle-free rhFIB protein. The present invention
satisfies this need. It has been Surprisingly found that trans
genic animals can be genetically engineered to produce and
secrete into readily accessible body fluids therapeutically
useful quantities of rhFIB. In addition to therapeutic uses
involving replacement or addition therapy, the FIB of the
invention finds us in a variety of applications, such as a “glue'
in Surgical procedures, as a delivery system for drugs, such as
antibiotics or anti-parasitic agents, to wounds, as a food Sub
stitute, and for altering the composition of milk. These trans
genic systems are described below.
SUMMARY OF THE INVENTION

40

cost of treatment, and are not risk free. There is thus a critical

need for a source of this protein alternate to human plasma.
An important advance in obtaining an alternate clinical
source of FIB has been the cloning of cDNAs encoding the
three different fibrinogen chains, and the publication of
cDNA sequences. Rixon et al., Biochemistry 22:3237 (1983);
Chung et al., ibid: 3244; Chung et al., ibid: 3250. The struc
ture of the FIB molecule is exceedingly complex. Each mol
ecule of FIB consists oftwo sets of three different polypeptide
chains, designated AC, Bf3 and Gy, with molecular masses of
66 kDa, 52 kDa and 46.5 kDa, respectively. The two half
molecules containing each set of chains are linked together by
three disulfide bonds. In addition, a complex set of intra- and
inter-chain disulfide bonds (there are a total of 29 disulfide
bonds with no free sulfhydryl groups) are involved in main
taining proper functional structure. Further, FIB is a glyco
protein with highly specific glycosylations. The molecule
contains four carbohydrate chains, one each on the B. B. G
and Y chains; the C. and A chains contain no carbohydrate.
About 11 kDa of the total molecular mass of FIB (340kDa) is
attributable to this carbohydrate, added to the molecule post
translationally. In addition, isoforms of glycoproteins are
known corresponding to differences in Sialic acids on the
carbohydrate chains. Proper carbohydrate modification is
required for functional activity of FIB.

gen chains that bear carbohydrates cannot be produced in
prokaryotes.
Individual FIB chains have been expressed in COS1 (trans
formed monkey kidney fibroblast) cells. Danishevsky et al.,
Biochim. Biophys. Acta 1048: 202 (1990). In addition, trans
fecting COS1 cells with a combination of cDNAs encoding
the individual human fibrinogen subunit chains is reported to
produce the holoprotein, but the amounts produced were
Small, and Substantially less than the production achieved in
the transgenic animal systems to be described below. Roy et
al., J. Biol. Chem., 266: 4758 (1991). The secretion of par
tially assembled or wholly unassembled and separate human
FIB (“hFIB) or recombinant human FIB ("rhFIB) chains
has not been reported for native or genetically engineered
tissues. Chung et al. (1983); Danishevsky et al (1990). In

45
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In accordance with the present invention, there is provided
a non-human mammalian animal that has stably integrated
into its genome heterologous (that is, exogenously derived)
polynucleotides that encode the AC, BB and GY polypeptide
chains of human FIB, and that direct by means of regulatory
and signal sequences the expression of biologically active
rhFIB in mammary gland cells, such that newly synthesized
fibrinogen is secreted into bodily fluid compartments, par
ticularly milk, blood or urine of the animal. By integrating
fewer than all of the three heterologous polynucleotides, indi
vidual chains of fibrinogen can be produced and may be
secreted. By integrating heterologous polynucleotides that
have been modified prior to administration to the host animal,
modified FIB and products thereof can be produced.
It therefore is an object of the present invention to provide
transgenic animals capable of producing rhFIB, individual
polypeptide subunit chains of FIB, or FIB-derived proteins
and protein products.
It is also an object of the invention to provide a means of
producing rhFIB, individual polypeptide subunits thereof, or
FIB-derived proteins and protein products in transgenic ani
mals.

65

In a preferred embodiment of this aspect of the invention,
lactating transgenic animals produce the rhFIB, individual
FIB subunits or FIB-derived proteins in their mammary
glands and secrete these products in their milk. In another

US 7,435,869 B2
3
preferred embodiment, transgenic animals secrete the pro
duced rhFIB, individual FIB subunits, or FIB-derived pro
teins in their blood and/or urine.
BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a sketch of the murine WAP gene.
FIG. 2 is a sketch of the plasmid puCWAP4 cassette vector
containing -2.6 kbp of WAP 5" promotor region, ~1.3 kbp of
WAP 3' UTR and flanking 3' region.
FIG.3 is a sketch of the plasmidpUCWAP5 cassette vector
containing the WAP fragment of puCWAP4 with added Not

5

10

Animals
15

25

30

40

FIB, and modified FIB subunit chains in amounts and in

45

The term “animal’ here denotes all mammalian animals

except humans. It also includes an individual animal in all
stages of development, including embryonic and fetal stages.
A “transgenic' animal is any animal containing cells that bear
genetic information received, directly or indirectly, by delib
erate genetic manipulation at the Subcellular level. Such as by
microinjection or infection with recombinant virus.
“Transgenic’ in the present context does not encompass
classical crossbreeding or in vitro fertilization, but rather

duced into the embryo, and the embryo then develops into a
transgenic animal. In a preferred method, developing
embryos are infected with a retrovirus containing the desired
DNA, and transgenic animals produced from the infected
embryo. In a most preferred method, however, the appropriate
DNAs are coinjected into the pronucleus or cytoplasm of
embryos, preferably at the single cell stage, and the embryos
allowed to develop into mature transgenic animals. Those
techniques as well known. For instance, reviews of standard
laboratory procedures for microinjection of heterologous
DNAS into mammalian (mouse, pig, rabbit, sheep,goat, cow)
fertilized ova include: Hogan et al., MANIPULATING THE
MOUSE EMBRYO, Cold Spring Harbor Press, 1986:
Krimpenfort et al., Bio/Technology 9: 86 (1991); Palmiter et
al., Cell 41:343 (1985); Kraemeret al., GENETIC MANIPU
LATION OF THE EARLY MAMMALIAN EMBRYO, Cold

50
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denotes animals in which one or more cells receive a recom

binant DNA molecule. Although it is highly preferred that
this molecule be integrated within the animal’s chromo
Somes, the present invention also contemplates the use of
extrachromosomally replicating DNA sequences, such as
might be engineered into yeast artificial chromosomes.
The term “germ cell line transgenic animal' refers to a
transgenic animal in which the genetic information has been
taken up and incorporated into a germ line cell, therefore
conferring the ability to transfer the information to offspring.
If Such offspring in fact possess Some or all of that informa
tion, then they, too, are transgenic animals.

Advances in technologies for embryo micromanipulation
now permit introduction of heterologous DNA into fertilized
mammalian ova. For instance, totipotent or pluripotent stem
cells can be transformed by microinjection, calcium phos
phate mediated precipitation, liposome fusion, retroviral
infection or other means, the transformed cells are then intro

35

forms that are Suitable for treating humans with genetic or
acquired deficiencies of the normal protein.
Glossary

The transgenic animals of this invention may be any ani
mal, other than human, that produces milk, blood serum, and
urine. Farm animals (pigs, goats, sheep, cows, horses, rabbits
and the like), rodents (such as mice), and domestic pets (for
example, cats and dogs) are included in the scope of the
present invention.
Stable Integration of DNA Constructs in Animal Genome
It is highly preferred that the transgenic animals of the
present invention be produced by introducing into single cell
embryos appropriate polynucleotides that encode human
holoFIB, or individual subunit chain polypeptides or modi
fied products thereof, in a manner Such that these polynucle
otides are stably integrated into the DNA of germline cells of
the mature animal and inherited in normal mendelian fashion.

DETAILED DESCRIPTION OF PREFERRED
EMBODIMENTS

An approach has been discovered to producing non-hu
man, transgenic mammalian animals that are genetically
engineered to secrete, into readily accessible body fluids Such
as milk, blood and urine, recombinant holofibrinogen (for
example, rhFIB), individual subunit chain polypeptides of

otherwise, the abbreviations FIB or hFIB or hrFIB as used

herein will refer to this holoprotein.

I linkers.

FIG. 4 is a sketch of the puCWAP5 plasmid incorporating
a polynucleotide encoding the FIBAC. 1 chain.
FIG. 5 is a sketch of the puCWAP5 plasmid incorporating
a polynucleotide encoding the FIB Bf 1 chain.
FIG. 6 is a sketch of the puCWAP5 plasmid incorporating
a polynucleotide encoding the FIBGY 1 chain.
FIG. 7 shows the family tree of transgenic mice that have
incorporated into their genome DNAS encoding FIB genes.
FIG. 8 is a schematic of the means for separating endog
enous from rhFIB in mouse milk whey and plasma.
FIG. 9 shows a Western blot under non-reducing condi
tions of transgenic rhFIB in mouse whey and plasma.
FIG. 10 shows the same experiment as in FIG. 9, except
that the gel was run under reducing conditions.
FIG. 11 shows an SDS-PAGE separation of rhFIB after
digestion with thrombin.
FIG. 12 shows the results of assays for thrombinopeptide A
after digestion by thrombin of rhFIB.

4
The information to be introduced into the animal is pref
erably foreign ("heterologous') to the species of animal to
which the recipient belongs, but the information also may be
foreign only to the particular individual recipient, or genetic
information already possessed by the recipient. In the last
case, the introduced gene may be differently expressed than is
the native gene.
By “holofibrinogen' is meant the mature, fully glycosy
lated, physiologically functional fibrinogen. Unless specified

60
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Spring Harbor Laboratory Press, 1985; Hammer et al.,
Nature, 315: 680 (1985); Purcel et al., Science, 244: 1281
(1986); Wagner et al., U.S. Pat. No. 5,175.385; Krimpenfort
et al., U.S. Pat. No. 5,175,384, the respective contents of
which are incorporated by reference. The human FIB or FIB
Subunit genes can be obtained by isolating them from an
appropriate genomic source (i.e., human liver, which is the
natural organ for production of this protein) by alternate
methods which include preparation of cDNAs from isolated
mRNA templates, direct synthesis, or some combination
thereof. The cDNAs encoding individual FIB chains can be
fused, in proper-reading frame, with appropriate regulatory
signals as described in detail below, to produce a genetic
construct that is then amplified, for example, by preparation
in a bacterial vector, according to conventional methods. See,
for example, the standard work: Sambrook et al., MOLECU
LAR CLONING: A LABORATORY MANUAL, Cold

Spring Harbor Press, 1989, the contents of which are incor

US 7,435,869 B2
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porated by reference. The amplified construct is thereafter
excised from the vector and purified for use in producing
transgenic animals. Purification can be accomplished by
means of one or more cycles of anionic HPLC: alternate
techniques include ultracentrifugation through a Sucrose or
NaCl gradient, gel electroelution followed by agarose treat
ment and ethanol precipitation, or low pressure chromatog
raphy. Purification by several cycles of HPLC allows for
remarkably high transformation frequencies, on the order of
20% or more in both mice and pigs.
Although the present invention preferably entails the use of
DNA constructs that produce the desired or native human FIB
per se, the desired protein may also be produced as a fusion
protein containing another protein. For example, the desired
recombinant FIB protein of this invention may be produced as
part of a larger recombinant protein in order to stabilize the
desired protein or to make its purification from milkfaster and
easier. The fusion partners are then separated chemically or
enzymatically, and the desired FIB isolated. Production of a
fusion product between FIB and B-lactoglobulin (BLG) or
between FIB and another milk protein are contemplated.
The rhEIB may also be produced having the identical
sequence as the native molecule, or it may be produced as a
fragment or derivative. A variety of modified rhFIB or sub
units thereof can be produced by altering a cloned DNA using
the well-known techniques of in vitro mutagenesis such as

10

15

RECOMBINANT TECHNOLOGY IN HEMOSTASIS

25

those set out in the references above.

Production of transgenic animals containing the gene for
human FIB involves the use of cDNA or genomic DNA that
encodes the C, B, and Y chains of hFIB. See Rixon et al., 1983,
and Chung et al., 1983, supra. The full-length base sequence
of each chain is provided in these references, the contents of
which therefore are incorporated by reference.
DNA constructs useful in the present invention provide a
double stranded DNA sequence encoding FIB operably
linked to all of the cis-acting signals necessary for mammary
gland-specific expression of this protein, post-translational
glycosylation of two of the three sets of chains of FIB (B?3 and
GY), secretion of FIB into milk or other body fluids, and
expression of full biological activity. As set out above, poly
nucleotides encoding FIB or FIB subunit chains suitable for
use in the invention can be isolated by Standard techniques
starting from the known polynucleotide sequences.
Modified FIBDNA sequences also can be employed in this
invention. Useful modifications within this context include,

but are not limited to, those that alter post-translational modi
fications, size or active site of FIB, or that fuse this protein or
portions thereofto another protein. Such modifications can be
introduced into the protein by techniques well known in this
art, Such as by synthesizing modified genes by ligation of
overlapping oligonucleotide or introducing mutations into
the cloned genes by, for example, oligonucleotide-mediated
mutagenesis. See, for example, Ebert et al., Bio/Technology 9:
835 (1991), Denman et al., loc. cit.: 839 (1991), and Gerardet
al., Science 248: 1421 (1991), for details of procedures for
site mutagenesis of proteins. One or more FIP glycosylation
sites can be eliminated or changed by site mutagenesis, for
instance. Another variant might be a chimeric FIB having a
tissue growth factor as protease inhibitor peptide attached to
the nascent FIP polypeptide during transgenic biosynthesis or
by co-current translation. The assembly of the complex hex
americ structure may be exploited to include a guest mol
ecule, but while maintaining recognition of the FIB complex
for secretion. Specific changes of entire domains within FIB
could be used to impact specialized activity of other mol
ecules, but still remain the hexameric structure required for
secretion.

6
The cis-acting regulatory regions useful in the invention
include the promoter that drives expression of the FIB or FIB
Subunit chain genes. Highly preferred are promoters that are
specifically active in mammary gland cells and that involve
milk proteins. Among Such promoters, highly preferred are
the whey acidic protein (WAP), short and long C, B and kappa
casein, C.-lactalbumin and B-lactoglobulin (“BLG”) promot
ers. Promoters may be selected on the basis of the protein
compositions of various milks.
For example, the WAP and BLG promoters are particularly
useful with transgenic rodents, pigs and sheep. The rodent
WAP short and long promoters have been used to express the
rat WAP gene, the human tA gene and the CD4 gene, while
the sheep BLG promoter has been used to express the sheep
BLG gene, the human alpha-1-antitrypsin gene and the
human Factor IX gene. For reviews, see Paleyanda et al. in
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AND THROMBOSIS (eds. Hoyer et al.), Plenum Press, NY
(1991), at page 197; Clarket al., TIBTECH 5:20 (1987), the
respective contents of which are incorporated by reference.
Preferred among the promoters for carrying out the present
invention are the rodent casein and WAP promoters (see, for
example, Rosen, U.S. Pat. No. 5,304,489, and Meade, U.S.
Pat. No. 4,873.316) and the casein, C.-lactalbumin and BLG
promoters (Strijkeret al., U.S. Pat. Nos. 5,322,775 and 5,366,
864) from porcine, bovine, equine and ovine (pigs, sheep,
goats, cows, horses), rabbits, rodents and domestic pets (dogs
and cats); accordingly, the respective contents of the afore
mentioned patents are incorporated by reference. The genes
for these promoters have been isolated and their characteriza
tions published. For reviews see Clarket al. (1987), supra, and
Henninghausen, Protein Expression and Purification 1: 3
(1990). The mouse WAP promoter is commercially available:
see ATCC catalogueno. 63005 (2d ed., 1991), Rockville, Md.
The promoter may be isolated by carrying out conventional
restriction endonuclease and Subcloning steps. A preferred
mouse WAP promoter can be isolated as a 2.6 kb EcoR1
Kpn1 fragment which is immediately 5' to the WAP signal
sequence. The “long WAP promoter the 5' 4.2 kb Sau3A
Kpnl promoter of the mouse WAP gene, or a fragment
thereof is also suitable for carrying out the present inven
tion (see, Paleyanda et al., 1991 above; Henninghausen, 1990,
above).
Important to the present invention are regulatory sequences
that direct secretion of proteins into milk and/or other body
fluids of the transgenic animal. In this regard, both homolo
gous and heterologous regulatory sequences are useful in the
invention. Generally, regulatory sequences known to direct
the secretion of milk proteins, such as either signal peptides
from milk for production of individual FIB subunit chain
polypeptides or the nascent target polypeptide for production
of the holoFIB, can be used. Signal sequences also can be
used in accordance with this invention that direct the secre
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tion of expressed proteins into other body fluids, particularly
blood and urine, such as signal sequences for coagulation
proteins such as protein C and Factor VIII.
Unexpectedly, it has been found that a trigenic animal can
efficiently express three separate transgenes which do not
have a signal peptide operably linked between promoter and
encoding DNA sequences, but still direct synthesis and secre
tion of a assembled recombinant human fibrinogen protein in
milk of a transgenic animal. This occurs in a temporally
regulated way as to enable a complex asymmetric assembly
of the fibrinogen polypeptides which nascent polypeptides
then enables subsequent secretion of the hexameric, 340 kDa
protein in milk. It is important to note that, in general, mam
malian cells do not efficiently secrete separate fibrinogen
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chains. See Danishefsky et al., Biochim. Biophys. Acta 1048:
202 (1990), and Hartwig et al., J. Biol. Chem., 266: 6578
(1991). This phenomenon has been explained by Danishefsky
et al. to be a consequence of proper folding rather than the
presence of a specific domain within one of the component
chains that may be a prerequisite for fibrinogen secretion;
this, since neither of the three chains of fibrinogen by them
selves have the integral signal for secretion. A separate, iden
tifiable signal sequence therefore does not appear to exist in
any of the individual C, B and Y polypeptides (and, hence,
there is no signal sequence encoded immediately preceding
the coding sequence for any of the nascent polypeptides in the
cDNA or genomic sequences offibrinogen chains) for direct
ing secretion. Importantly, it has been discovered discovered
that it is not necessary to add any coding for milk protein or
other specific signal sequences to the fibrinogen cDNAS used
to make trigenic mice, pigs and cows which secrete properly
folded and active transgenic hFIB. The highly preferred con
structs consist of three separate transgenes; each transgene
has the 2.5 kb-WAP-promoter ligated directly to the native
cDNA for one the C.B., and Y FIB polypeptides with no inter
Vening signal sequence.
As noted above, there is no requirement for a coding DNA
for signal peptide sequences in each of the present three FIB
polynucleotide constructs when producing holoFIB. The
prior art does not suggest this fact, nor does it presage a
properly folded, complex recombinant fibrinogen structure
which specifically enables the mammary tissue Golgi trans
port system to efficiently secrete the assembled FIB. The
present examples have three salient features which show that
indeed the mammary tissue can perform Such a task. First, the
levels of rFIB found are consistent with the stable expression
levels found for prior examples of 2.5 kb 5’-WAP promoter
cDNA single gene, single polypeptide expressions in the milk
of transgenic mice (i.e., about 1-100 g/ml, Hennighausen et
al., above). Second, the transgenic mice secrete fibrinogen
without involution as indicated by their normal lactation and
pup weight gain. Third, the recombinant fibrinogen secreted
is physiologically active. Thus, in combination, these results
Suggest that no significant intracellular buildup of assembled
fibrinogen occurs in the mammary epithelium which is suffi
cient to halt lactation. Likewise, no appreciable secretion of
individual unassembled polypeptides occurred in trigenic-C.
B.Y-fibrinogen mice.
In contrast to the trigenic animal, it appears that a signal
peptide is needed for each cDNA sequence encoding C, B and
Y if the unassembled, individual chains are to be efficiently
secreted from the mammary epithelium.
Among the useful sequences that regulate transcription, in
addition to the promoters discussed above, are enhancers,
splice signals, transcription termination signals, and polyade
nylation sites. Particularly useful in this regard are those that
increase the efficiency of the transcription of the genes for
fibrinogen in the mammary gland cells of the transgenic ani
mals listed above. Preferred are transcription regulatory
sequences for proteins highly expressed in the mammary
gland cells (see above).
Preferably, the expression system or construct of this
invention also includes a 3' untranslated region downstream
of the DNA sequence encoding the desired recombinant protein, or the milk protein gene used for regulation. This region
apparently stabilizes the RNA transcript of the expression
system and thus increases the yield of the desired protein.
Among the 3' untranslated regions useful in this regard are
sequences that provide a polyA signal. Such sequences may
be derived, for example, from the SV40 small tantigen, from
the casein 3' untranslated region, and from other 3' untrans

8
lated sequences well known in this art. Preferably, the 3'
untranslated region is derived from a milk-specific protein.
The stabilizing effect of this region's poly A transcript is
important in stabilizing the mRNA of the expression
5 sequence. Also important in increasing the efficiency of
expression of FIB are ribosome binding sites. Likewise,
sequences that regulate the post-translational modification of
FIB subunits are useful in the invention.
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Pursuant to the present invention, therefore, a double
stranded chimeric DNA, including genes that code for the FIB
Subunit chains and that are operably linked to cis-acting regu
latory sequences which promote efficient expression of the
former in milk and/or other body fluids, are introduced into an
embryo, where they are integrated into the embryonic
genome and become part of the inheritable genetic endow
ment of all of the animals cells, including the germline cells,
of the adult which matures from the embryo. The FIB thus
expressed and secreted into milk is immunologically reactive,
as measured by an ELISA assay described below.
Where the synthesis of a FIB subunit chain may be limiting
in the production of-the holoprotein, expression of this chain
an be increased by placing the gene in a different genomic
locus. This otherlocus can contain a DNA sequence under the
same or a different regulatory sequence than the other two
FIB sequences.
In a particularly preferred embodiment the transgenes of
the invention generally consist of milk protein upstream and
downstream and flanking sequences in combination, sepa
rately, with each of the three translated portions of the cDNA
sequences representing the three FIB subunit chains. A native
5'-WAP regulatory sequence ending in an accessible restric
tion site immediately before/at the ATG codon may be ligated
to each of the respective restriction sites which occur at the
ATG of translatable sequences with no linker sequences
derived from the chains of human FIB. A restriction site may
be made through site mutagenesis of three bases located in
each 3'-untranslatable sequences of the three FIB cDNAs.
This preserves the stop sequence, while adding a restriction
site immediately after each of the translatable sequences of
the FIB cDNAs. Each of the combined 5'-regulatory and FIB
translatable sequences which end in a particular restriction
site then can be ligated to a corresponding restriction site
which occurs at the beginning of the 3'-untranslated region of
WAP and adjoining WAP 3'-flanking region. This construc
tion motifenables native 5'-regulatory and 3'-UTR of the milk
protein genes to be immediately juxtaposed without interven
ing sequences (but see above relating to the insertion of the
BB gene at a different locus). Particular restriction sites at the
ends of all constructs may be selected in order to facilitate
concatenation of AC, BB and GY constructs into a single
domain within the animal genome.
Although the foregoing, general description of the DNA
constructs within the present invention relates in several
places to the WAP promoter, it is emphasized that other suit
able promoters (see above for discussion) can be ligated to the
fibrinogen encoding polynucleotides in a similar manner. By
way of illustration, the following discussion describes the use
of the bovine lactoglobulin (“BLG”) promoter to increase the
efficiency of expression of FIB and FIB-BLG fusion proteins
in mammary glands.
Using techniques described above, fibrinogen encoding
cDNA may be inserted into an ovine BLG gene. In order to
produce Such a construction, for instance, the 11.2 Kbp ovine
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BLG gene may be modified to possess a unique EcoRV site
upstream of the initiator ATG codon in the vectorpUCXSRV.
The sequence around this region is changed as follows:
5

PWI

MetLys

Seq. ID No. 1

Natural CCCCAGCTGCAGCCATGAAG

EcoRV
MetLys
pUCXSRV CCCCAGGGATATCCCTGCAGCCATGAAG

Seq. ID No. 2

This allows the cloning of bluntend fragments upstream of
the BLG gene. The 1.5 kbp fragment from a plasmid (e.g.,
pWAPFIB) which contains a cDNA encoding human fibrino
gen is isolated, blunt ends are generated with T4DNA poly
mer, and the product is ligated to EcoRV-cleaved puCXSRV.
Following transformation of E. coli with this plasmid, clones
that are produced can be characterized by restriction analysis
of plasmid DNA prepared by a mini-prep method and by
determination of the nucleotide sequence around the 5' and 3'
cloning junctions for the DNA. Clones having the desired
structure can be used to produce transgenic rodents, pigs,
sheep, cows, horses and other farm animals and domestic pets
(cats and dogs) that secrete a FIB-BLG fusion product into
their biological fluids as described below.
A hFIB genomic sequence also may be fused to the ovine
BLG promoter illustrated in the following discussion. DNA
sequences encoding ovine BLG in plasmid puCXSRV are
deleted to generate a vector containing only ovine BLG pro
moter sequences(pUCSV). As with puCSRV, blunt-ended
fragments can be fused to this promoter region by ligation to
a unique EcoRV site. The sequences 5' to this site are identical
in both plasmids.
Genomic FIB sequences of greater than about 15 kbp can
be introduced into transgenic animals, despite-their length,
through the use of cosmids with overlapping FIB sequences,
whereupon the necessary assembly of an entire genomic
polynucleotide encoding hEIB is achieved by homologous
recombination in vivo after microinjection into an embryo
cell. In constructs useful in the foregoing example, a plasmid
in which the FIB genomic sequences are fused to ovine BLG
3' flanking sequences just after the fibrinogen translation ter
mination codon to ensure proper transcription, termination
and polyadenylation. The hFIB gene fused to ovine BLG 3'
flanking sequences is excised from the plasmid, the 3' over
hangs repaired using Klenow enzyme, and the product ligated
to EcoRV-cleaved PUCSR. Following transformation of E.
coli, the resulting clones are characterized by restriction DNA
analysis and by determining the nucleotide sequences around
the 5' and 3' cloning junctions. Clones having the desired
structure may be introduced into fertilized animal ova for
production of transgenic animals.
A variety of vectors based on the BLG gene may be con
structed. In constructs based on this approach, the sequences
encoding the ovine BLG protein are deleted, but the 5' pro
moter sequences are retained. Each may possess a different
complement of introns from the ovine gene and a unique
EcoRV site allowing the cloning of blunt ended fragments
between the promoter and 3' flanking region of the gene.
However, each contains the BLG promoter, the EcoRV site
and the BLG 3'-flanking sequence. For each recombinant, the
1.5 kbp. KpnI fragment from pWAPFIB is isolated, bluntends
generated as above, and the product ligated to EcoRV-cleaved
vector sequences. Those constructs with the proper struc
tures, determined as described above, can be used to express
FIB in the biological fluids of transgenic animals.
A notable result is obtained with doubly-transgenic mice
that are produced having native BLG genomic sequences

10

10
which were injected as separate constructs to be concatenated
in vivo, as additional flanking sequences to the BLG target
cDNA construct (such as, BLG promoter-Intron I-EcoRV
Intron VI-BLG 3' flank plus BLG). In particular, such mice
give higher expression more frequently than do mice pro
duced using constructs of the BLG promoter-FIB cDNA
BLG gene or BLG promoter-FIB genomic (thBLG 3' end).
Intact or native BLG genomic sequences that are preligated to
the BLG-cDNA target may give the same advantage. The
same principle applies, mutatis mutandis, to WAP genomic
Sequences.
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Isolation of Milk from Lactating Transgenic Animals
Obtaining milk from a transgenic animal according to the
present invention is accomplished by conventional means.
See, for example, McBurney et al., J. Lab. Clin. Med. 64: 485
(1964); Velander et al., Proc. Nat'l Acad. Sci. USA 89:12003
(1992), the respective contents of which are incorporated by
reference. Fibrinogen or Subunit chains or protein products
thereof can be isolated and purified from milk or urine by
conventional means without deleteriously affecting activity.
A highly preferred method entails a combination of anion
exchange and immunochromatographies, cryoprecipitations,
and zinc ion-induced precipitation of either whole milk or
milk whey (defatted milk) proteins. For these techniques, see
Bringe et al., J. Dairy Res. 56:543 (1989), the contents of
which is incorporated herein by reference.
Milk is known to contain a number of proteases that have
the potential to degrade foreign proteins. These include in the
main an alkaline protease with tryptic and chymotryptic
activities, a serine protease, a chymotrypsin-like enzyme, an
aminopeptidase and an acid. protease. Clark et al. (1987),
supra. It may be desirable, therefore, to protect newly
secreted FIB or subunit chains thereof against proteolytic
degradation. Such precautions include rapid processing of the
milk after collection and addition to the milk of well known
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inhibitors of proteolysis, such as are listed in SIGMA
CHEMICAL CO. CATALOG, 1993 edition, at page 850.
Detection and Quantification of Transgenic FIB
The present inventors have used two sandwich ELISA
formats to detect and quantify FIB in milk whey. One tech
nique is a polyclonal antibody capture/FIB/monoclonal anti
body detection system (“P/M) and the other which uses
polyclonal antibodies both for capture and for detection (“P/
P”). Both methods are described below. The P/M system
benefits from greater specificity for hFIB as it recognizes only
one epitope of about 6 to 20 amino acids in length specific to
hFIB. However, because the P/M system recognizes only a
single epitope, detection sensitivity is reduced. In contrast,
the P/P system will provide less specificity as it recognizes
many epitopes, but at the same time will provide greater
detection sensitivity. As these multiple epitopes include
epitopes conserved between mouse and human FIB, the back
ground “FIB' signal is increased when measuring rhFIB in
mouse milk by the P/P system. Detailed sandwich ELISA
procedures are provided in EXAMPLE 7 below.
Purification and Biological Activity of Secreted Recombinant
Fibrinogen
Mammalian proteins associated with hemostasis are well
conserved with respect to structure and function and thus it is
necessary to both identify and purify rFIB from host body
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fluids. To establish that the FIB secreted in the milk of trigenic
animals is indeed authentic, i.e., physiologically active, het
erologous FIB, a number of well known, standard techniques
may be carried out; these are listed below:

12
The present invention is further described by reference to
the following illustrative examples.

Physical Techniques

WAP-Fibrinogen cINA Constructs for Expression
of Fibrinogen in Transgenic Animals

EXAMPLE 1.

(1) Physical separation and identification. A sequence of

ion exchange chromatography and Zn’-- selective precipita

Construction of Cassette Vectors

tion achieves two main goals: the reduction of background
protein (i.e., host FIB) from milk and an efficient isolation of
rhFIBaway from contaminating host FIB. Host FIB is present
to a very small extent from natural passover of serum proteins
into milk, but it is predominately due to injury of the mam
mary tissue from the milk collection process. Over half of the
background milk proteins can be removed by anion exchange
chromatography. Over 75% of the casein will be removed by

FIB subunit chain DNAs, tissue-specific promoters, and
secretion signal sequences were obtained from sources
described above. FIB subunit chain cDNAs were cloned into
15

the Zn-- selective precipitation process. The resulting rhFIB

will be about 20-30% pure at this stage with an overall yield
of about 50%. Control host milk whey serves as a negative
human FIB control, and control whey doped with authentic
human FIB serves as a positive control for human FIB. Trans
genic whey serves as the source of recombinant FIB. The
non-doped control whey contains host FIB that primarily

25

partitions into a second 24 mM Zn-- supernatant fluid. Only

about 1-3% of the FIB present in the final purified human or

rhFIB samples will be host FIB. Thus, the Zn-- selective

procedure enables an efficient separation of rhFIB from host
FIB.

(2) Silver staining of SDS-PAGEgels of isolated rhFIB.
(3) Western blot analyses of isolated rhFIB.
(4) Fibrinopeptide A detection by EIA in thrombin-treated
samples.

30

35

Biochemical Tests

(5) Using ELISA signals (using detection by polyclonal
anti-human fibrinogen antisera found in the Supernatants after
centrifugation to remove precipitates and/or clots) to track the
consumption of isolated rhFIB by human thrombin.
(6) Determination of the apparent molecular weights of the
assembled FIB molecule and of the separate C.B., and Y chains
found under reducing conditions.
(7) The formation of a fibrin-like clot after treatment of the

40

45

isolated rhEIB with human thrombin.

(8) The formation of C.B., and Y fibrin chains in these same

50

clots.

(9) The release of fibrinopeptide A to confirm biological
activity of isolated rhFIB by conversion to fibrin upon reac
tion with human thrombin.

For sources of these well-known techniques see, for
example, Hartwig et al., J. Biol. Chem., 266: 6578 (1991);
Koopman et al., J. Biol. Chem., 266: 13456 (1991); Lonnerdal
et al., J. Appl. Biochem., 4: 203 (1982); Farrell et al., Bio
chem., 30: 9414 (1991); Goding, MONOCLONAL ANTI

55
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BODIES: PRINCIPLES AND PRACTICE, Academic Press,

NY: Bolyard et al., Gene 66: 183-(1988); Hartwig et al., J.
Biol. Chem., 266: 6578 (1991); Roy et al., loc. cit., 266: 4758
(1991); Dempfie et al., Thrombosis Res., 46: 19 (1987);
Dempfie et al., loc. cit., 48: 223 (1987); and Yu et al., Bio
chem. Biophys. Res. Commun., 96: 1032 (1980), the respec
tive contents of which are incorporated by reference.
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a modified puC 18 vector, and grown up in E. coli JM109.
A puC18 vector (GIBCO-BRL, Gaithersburg, Md.) was
digested with HindIII+EcoRI restriction endonucleases,
blunted with T4DNA polymerase in the presence of 100 mM
dNTPs, and a Not I linker was ligated into the former HindIII
EcoRI multiple cloning site. This modified puC fragment
was additionally digested with Not I+ enzyme to remove
extra (multiple copies) Not linker sequences arising from
ligation, and then religated and grown up in E. coli JM 109.
This procedure modified the puC18 vector by removing the
entire multiple cloning region of puC18 (including the Kpn I
site) and replacing it with a Not I restriction site. The new
vector was designated puCNot1+.
A pUC vector containing -2.6 kbp of WAP 5' promoter
region, -1.3 kbp of WAP3' UTR and flanking 3", but no WAP
coding or intronic regions was constructed (designated cas
sette vector pUCWAP4, FIG. 2; see WAP gene, FIG. 1, and
cassette vector puCWAP5, FIG. 3). The entire murine WAP
gene including 2.6 kb of 5' untranslated sequence and 3'
untranslated region may be obtained from Dr. I. Hen
nighausen, National Institutes of Health, Bethesda, Md. See,
Campbell et al., Nucleic Acids Res., 12:8685 (1984). The
WAP fragment contained within the WAP4 vector contains a
-2.6 kbp WAP promoter 5' region beginning at EcoRI#1 and
ending at the translational start site of WAP which is imme
diately downstream of the unique Kipn I endonuclease restric
tion site (see FIG. 1). To this KpnI site was ligated a fragment
of-1.3 kbp of WAPUTR and flanking 3' sequence. This WAP
3' DNA included the region from immediately downstream of
the WAP stop codon down to the EcoRI#2 site. The WAP
fragment contained in WAP4 was excised from the puC
vector using EcoRI, and then blunted, and NotI linkers were
added, further trimmed by NotIdigestion, and ligated into the
pUCNotI+ plasmid which had been linearized with NotI
restriction endonuclease. The resulting plasmid was desig
nated puCWAP5 (see FIG. 3).
Amplification by PCR of Fibrinogen Subunit Chain cDNAs
Each of the cDNAs for AC, Bf3, and GY chains for human
fibrinogen were individually modified and amplified by poly
merase chain reaction (PCR) to create KpnI endonuclease
restriction sites on their 5' and 3' ends. The 5' KpnI site was
engineered by PCR using the primers containing the 6 base
sequence (GGTACC shown underlined in Table 1) that
immediately flanks the ATG start codon in the cDNAs of AC.
BB, and GY chains for hFIB. After amplification, the ends of
the extension using PCR products were blunted by T4-poly
merase (in the presence of deoxynucleosidetriphosphates to
inhibit processive exonuclease activity. In a similar fashion, a
KpnI site was engineered by site modification into the 6 base
sequence GGTACC shown underlined in Table 1 immedi
ately flanking the stop sequence in the 3' UTR of each cDNA
for AC, Bf3, and GY chains for hFIB. The complement of the
stop sequences is shown in bold in the 3' primers in Table 1.
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TABLE 1.

Oligonucleotides for Amplifying FIB Subunit Chain
cDNA

5

Seq. ID No. 3 AC. 5' GCTAGGTACCATGTTTTCCATGAGGATCGT
Seq. ID No. 4 AC 3' CAGTGGTACCCTAGACAGGGCGAGATTTAG

Seq. ID No. 5 B? 5' GCTAGGTACCATGAAAAGAATGGTTTCGTG

10

Seq. ID No. 6 Bf 3' CAGTGGTACCCTATTGCTGTGGGAAGAAGG

14
slab. The agarose band was then treated with agarase to
degrade and remove agarose contamination. After digestion,
the solution containing the cDNA was brought to 10 mM
Mg2+, 20 mM EDTA and 0.1% SDS and then extracted with
phenol/chloroform. DNA was precipitated from the aqueous
layer with 2.5 volumes of ethanol in the presence of 0.3 M
sodium acetate at -20°C. overnight. After centrifugation, the
pellet was washed with 70% ethanol, dried, and each of the
constructs was resuspended and dissolved in Brinster micro
injection buffer to a total (C, B, plus Y) concentration of about
1.2 to 5 lug/ml. Brinster et al., Proc Natl. Acad. Sci. USA
82:4438 (1985), incorporated by reference.

Seq. ID No. 7 GY 5' GCTAGGTACCATGAGTTGGTCCTTGCACCC
15

EXAMPLE 3

Seq. ID No. 8 GY 3' CAGTGGTACCTTAAACGTCTCCAGCCTGTT

Transgenic Mice

GGTACC = KipnI site
ATG = start codon

CTA and TTA = stop codon

2O

Construction of puC Plasmids Containing
Fibrinogen Subunit Chain cDNA
25

The blunted PCR products of the cDNAs for the BBand Gy
chains of human fibrinogen were digested with Kpnl restric
tion endonuclease. In the case of the AC chain, the PCR

Transgenic mice were produced essentially as described by
Hogan et al., Manipulating The Mouse Embryo, Cold Spring
Harbor Press, 1986, incorporated by reference. The proce
dures employed are outlined below.
Glass needles for micro-injection were prepared using a
micropipet puller and microforge. Injections were performed
using a Nikon microscope having Hoffman Modulation Con
trast optics, with Narashigi micromanipulators and a pico
injector driven by N (Narashigi).
Fertilized mouse embryos were surgically removed from
the oviducts of superovulated female CD-1 mice and placed

product was blunt-end cloned into puCNotI+ (which had 30
been digested with NotI and blunted with T4 Polymerase)
prior to partial Kpndigestion. This intermediate cloning and
partial digestion step was necessary to generate intact coding into M2 medium. Cumulus cells were removed from the
fragment due to the presence of an internal KpnI site within embryos with hyaluronidase at 300 ug/ml. The embryos were
the AC. chain cDNA. The intact AC. chain cDNA fragment was 35 then rinsed in new M2 medium, and transferred into M16
selected by gel electrophoresis, and cloned into the KpnI site medium for storage at 37° C. prior to injection.
Stock solutions containing about 1.2 g/ml (having about
at the junction between the WAP 5' promoter and WAP 3'
UTR/flanking sequences within the puCWAP5 plasmid. The 0.4 ug/ml each of the linearized constructs containing the AC.
KpnI-digested PCR products from Bf3 and GY chains for BB, and GY chains cloNAs for human fibrinogen, or about
human fibrinogen were each directly cloned into a 40 60-70 copies/pl of each construct) were prepared and micro
pUCWAP5 plasmid at the KpnI site. Separate electroporation injected into the pronuclei of 1 cell mouse embryos. In addi
transformation reactions were done on E. coli using each of tion, stock solutions containing about 5 g/ml total DNA
the three puCWAP5/fibrinogen cDNA preparations, and (having about 1.7 Lig/ml of linearized constructs containing
colonies were picked and grown up in TB amplicillin broth. 45 each of the AC, Bf3, and GY chains cDNAs for human fibrino
Plasmid preparations from these colonies were analyzed by gen or about 200 copies/pl of each construct) were prepared
restriction enzyme digestion and gel electrophoresis. The and microinjected into the pronuclei of 1 cell mouse embryos.
correct size and orientations were selected and one clone for
After injecting the DNA solution into the male pronucleus,
each WAP-fibrinogen cINA construct was sequenced at the embryos were implanted into avertin-anesthetized CD-1
WAP promoter 5':fibrinogen cDNA and fibrinogen cDNA: 50 recipient females made pseudo-pregnant by mating with
WAP 3' UTR and flanking junctions. Schematics summariz vasectomized males. About 25-30 microinjected mouse
ing the construction of the WAP-AC. (about 5.8 kbp). -Bf
embryos per recipient were transferred into pseudopregnant
(about 5.4 kbp), and -GY (about 5.2 kbp) cDNA plasmid and females. Embryos were allowed to come to term and the
linearized transgenes for human fibrinogen are given in FIGS. ss newborn mice were analyzed for the presence of the trans
4, 5, and 6, respectively.
gene by PCR using murine WAP and a FIB-specific primeras
described below.
EXAMPLE 2

Table 2 summarizes the embryo transfer data from an
experiment that produced transgenic fibrinogen-producing
Preparation of DNAs for Microinjection
60 mice. Separate PCR analysis for detection of each of the
cDNAs of fibrinogen was done on DNA purified from biop
The intact and linearized WAP 5' promoter/fibrinogen sied tail tissues by the method shown in Example 4 below. The
cDNA/WAP 3' UTR and flanking fragments were excised oligonucleotide primers shown in Table 3 were used to detect
from each puCWAP5 plasmids by NotI restriction endonu- as each of the FIB cDNAs. Detection of each chain required a
clease digestion and purified by low melting point agarose WAP oligonucleotide (no. 1 in Table 3) and one of the other
electrophoresis. The DNA:agarose band was cut from the gel oligonucleotides (Nos. 2, 3 or 4).

US 7,435,869 B2
15

16
Positive Fibrinogen Triple Construct F1's

TABLE 2

Transfers of Fibrinogen Constructs
Thirty transfers with the FIB constructs were performed. The three
Subunit chain constructs were coinjected at total DNA concentrations
of 1.2 g/ml and 5 g/ml or 200 total copies pland 800 total
copies.pl, respectively. Fourteen transfers were made with
1.2 g/ml-injected embryos and sixteen with 5 g/ml-inject embryos.
Eighteen Founder (“Fo') animals were produced that carried at least
one construct. Eight Fo mice were mated with control mice which
resulted in five lines transmitting the transgene. First generation
offspring (“F1') from lines 1, 23 and 85 have been bred and litters
produced.
1.2 Lig/ml
Transfers:

|B-Chain Positive Mice
23-2,23-7,23-1185-2
10

5 g/ml

14

16

68
696
480
34.2
6.2
11
78%

69
1098
675
42.1
5.3
13
81%

Mice tested:

68

69

Number transgenic:
Percent transgenic:

7
10%

11
15%

% Positive for C, B, Y:
C., f, Y Transgenic females:

85%
3

729%
3

Pups alive:
Embryos injected:
Embryos transferred:
Embryos per transferred:
Pups per litter
Transfers pregnant:
Pregnancy rate:

1-2,1-5, 1-6, 1-11,1-12, 1-14,1-16, 1-17.1-20,23-323-4,23-12,
109-3,109-4,109-5,109-10,109-11,112-3,112-6,112-7, 112-8

All embryos were injected with the three FIB constructs at
a total DNA concentration of 5ug/ml or about 200-300 copies
of each construct per pl.
A family tree of transgene passage from Fo to F1 females
is shown FIG. 7. Males were not retained.
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EXAMPLE 4

Transgenic Animal DNA

25

DNA can be prepared from tissue of a transgenic animal of
any species by the method exemplified below for mice. Mar
mur, J. Mol. Biol. 3:208 (1961), incorporated by reference.
A 5 mm piece of mouse tail was removed from young,
potentially transgenic mice at weaning (3 weeks) age, and
frozen in liquid nitrogen. To the frozen tissue was added 840
ul of Lysing Solution (8 mM EDTA-0.8% SDS-0.8%2-mer

TABLE 3

Oligonucleotide Primers Used for PCR Detection of
Human Fibrinogen Transgenic Mouse
Seq. ID No. 9.

Sense strand.

WAP-specific

5 - CTGTGTGGCCAAGAAGGAAGTGTTG-3

oligonucleotides.
Seq. ID No. 10. Antisense

AC. chain detection.

s' - GATGTCTTTCCACAACCCTTGGGC-3'

oligonucleotide.

Seq. ID No. 11. Antisense
BB chain detection.
oligonucleotide.

s' - CCCGATAGCCACCTCCTCTGATG-3'

Seq. ID No. 12. Antisense
GY chain detection.
oligonucleotide.

5 - CCTGGACTTCAAAGTAGCAGCGTC-3'

A Summary of the types of fibrinogen transgenic mice
detected in founder and offspring of founder mice is given in
Table 4. A listing of the positive FIB triple construct founders
(Fo) and a listing off-chain positive transgenic mice are also
given in Table 4.

45

mixture incubated at 50° C. The mixture was then extracted
50

TABLE 4

Transmission Frequency Genes Transmitted

1 (C., f, Y)
23 (C., B, Y)

9/13 (69%)
6/12 (50%)

109 (C, B, Y)
112 (C., f, Y)

5/11 (45%)
5/8 (62%)

85 (C., B)
113 (CBY)
89 (C)

with 250 ul of phenol/chloroform/isoamyl alcohol (25:24:1)
for 10-15 seconds, then centrifuged for 10 minutes. The
supernatant fluid (about 830 ul) was removed to a fresh tube,
and a DNA clot produced by vortexing the solution with 0.6
Vols. ofisopropanol. The mother liquor was decanted, and the
DNA clotrinsed twice with 80% ethanol. The DNA clot was

Transmission of Fibrinogen Transgenes
Mouse No.

captoethanol-80 ug/ml Proteinase K-1 M sodium chlorate in
40 mM TRIS buffer pH 8.0 and 120 mM. NaCl, and the

55

isolated by 5 minutes of centrifugation, aspiration of the
Supernatant fluid, and air drying of the clot with a stream of air
for 10 minutes.

60

1/6 (16%)

C., f, Y
C., f, Y (3/6);
B only 3/6)
C., f, Y
C., f, Y (46)
C. only (1/6)
C., Y only (1/6)
f only

Of8
Of6

None
None

65

The DNA clot was dissolved in 250 ul of TE buffer (10 mM
Tris.HCl, pH 7.0-1 mM EDTA, and the solution treated with
10 ul of a RNase mixture (1 mg/ml RNAse A and 4,000
units/ml RNAse T1) for 1 hat 37°C. This mixture was shaken
with 50 ul of a 24:1 (v/v) solution of chloroform-isoamyl
alcohol for 5-10 secs., centrifuged, and the supernatant fluid
transferred to a fresh tube.

The recovered Supernatant fluid above was mixed sequen
tially with 25 ul of 3 M sodium acetate and 0.5 ml of 95%
ethanol. The supernatant fluid was decanted from the precipi

US 7,435,869 B2
17
18
tated DNA, and the precipitate washed with 80% ethanol. The expression (the control over a rate limited B+ chain may be
purified DNA was isolated by centrifugation, air dried, then overcome by having a B+ allele with a more inducible loci).
dissolved in 150 ul of TE.
Furthermore, double and triple heterozygotes of the same
Essentially the same technique was used to prepare DNA gene (either A+ and/or B+ and/or G+) can be achieved to
from pigs, and the same or similar techniques can be used to 5 boost production levels (i.e., produce a A+B+G+, B+ animal
prepare DNA from other animals.
by crossbreeding a B+ animal, and further crossbreeding that
PCR reactions on DNA samples isolated from transgenic A+B+G+B+ animal with a different B+ line to obtain A+B+
animal tissue samples were carried out conventionally, as G+.B+B+).
described above. Concentrations of DNA isolates were deter

mined by measuring the absorbency at 260 nm of 1:20 dilu
tions of the TE solutions described above. A portion of the
sample was then diluted into 100 ul of TE to a concentration
of 30 ng/ul.

10

EXAMPLE 5

Transgenic Pigs

Embryos were recovered from the oviduct. They were
placed into a 1.5 ml microfuge tube containing approximately
0.5 ml embryo transfer media (phosphate buffered saline
PCR reaction mixtures (20 Il volume
+10% fetal calf serum, Gibco BRL). These were then centri
Component
Volume (ul)
Concentration
fuged for 12 minutes at 16,000xg RCF (13.450 RPM) in a
HOH
2O microcentrifuge (Allied Instruments, model 235C). Embryos
13.25
were removed from the microfuge tube with a drawn and
2.5
1
10x Taq buffer
dNTPs
2.0
O.2
polished Pasteur pipette and placed into a 35mm petridish for
MgCl2
1.5
1.5
examination. If the cytoplasm was still opaque with lipid Such
Primer 1
O.312S
O.S
that
pronuclei were not visible, the embryos were centrifuged
Primer 2
O.312S
O.S
Taq polymerase
O.12S
25 unitsul
25 again for 15 minutes. Embryos to be microinjected were
1.O
1.2 ng Lil
placed into a microdrop of media (approximately 100 ul) in
DNA template
the center of the lid of a 100 mm petri dish. Silicone oil was
used to cover the microdrop and fill the lid to prevent media
from evaporating. The petri dish lid containing the embryos
Procedure
was
set onto an inverted microscope (Carl Zeiss) equipped
Embryolysing buffer (5ul, 0.9% Nonidet P-40 and 0.9% 30
both a heated stage and Hoffman Modulation Contrast
Tween 20 in 20 mMTRIS buffer) was added to each PCR tube with
optics
(200x final magnification). A finely drawn (Kopf Ver
along with 1 ul of prepared DNA solution, and the mixture
overlaid with 25ul of mineral oil. The tubes were placed in an tical Pipette Puller, model 720) and polished (Narishige
automatic temperature cycler (Such as that manufactured by microforge, model MF-35) micropipette was used to stabilize
embryos while about 1-2 picoliters of HPLC-purified
N.J. Research) and heated to 98°C. for 2 minutes; the tem 35 the
DNA
solution containing approximately 200-500 copies of
perature was then brought down to 85°C.
DNA
construct
was delivered into the male pronucleus with
PCR reaction mixture (20 ul) was added to each tube and another finely drawn
micropipette. Embryos surviving the
40 cycles of the following protocol carried out:
microinjection
process
as judged by morphological observa
Denaturation at 96° C. for 20 seconds
tion
were
loaded
into
a
polypropylene tube (2 mm ID) for
40
Annealing at 55° C. for 1 minute
transfer into the recipient pig. Seven Surgical transfers of pig
embryos were made. These embryos had been coinjected
Elongation at 75° C. for 30 seconds
PCR reaction products were analyzed by running 20% of with the WAP-fibrinogen cINA constructs used in the above
the reaction mixture products on agarose gels and identifying mentioned transgenic fibrinogen mice only one of these
fragment sizes by comparison with marker DNA fragments. 45 recipient gilts was confirmed pregnant by ultrasound. The
(apparent) non-pregnant animals were kept to tentative term
FIG. 7 shows that a variety of founder animals having A+ as
their (potential) litter sizes may have been too small to
and/or B+ and/or G+ constructs can transmit all three or some
detect
by ultrasound analysis (In the past, three litters of four
of the A+, B+, and G+ transgenes. All animals were produced
piglets or fewer were not detected by ultrasound. Some of
from embryos having coinjections of the same DNA solution these
litters produced transgenic animals.)
containing all of the A+, B+, and G+ constructs. Detection of 50
A+, B+ and G+ DNAs was done by PCR as described above.
TABLE 5
Founder animals 1, 23, 109 and 112 had all three transgenes.
Founder animal 85 had only. A+ and B+. These founder
Fibrinogen Porcine Embryo Data
animals were outbred with control (nontransgenic) mice.
Transfer Totals
Animals 1 and 109 passed all three transgenes to 5 of 13 and 55
5 of 11 offspring, respectively, which is typical of Mendelian
Expt. 1
Expt. 2 Oct. 25, 1993
ID
genomic transmission for a single allele. Founder animals 23
Number
of
donors:
8
8
Transfer
#1
and 112 transmitted some transgene to 6 of 12 and 7 of 8
50 embryos
#129
animals, respectively. Several offspring of animal 23 had only Number of
261
283
Transfer #2
B+, while one offspring of animal 112 had only A+ and 60 ovulations:
47 embryos
#147
15

another had A+ and G+. Thus, founder animals 23 and 112 are

examples of triple transgenic animals having a confirmed
separate B+ allele in the case of animal 23 and having a
separate A+ and B+ allele in the case of animal 112. Founder
animal 85 is also an example of a mouse with a B+ only allele. 65
Thus, crossbreeding of animals having separate alleles and
therefore loci for each gene can be done in order to increase

Embryos collected:

250

296

Number of UFOs:
UFO's that cleaved:

99
29

77
6

Number injected:

141

219

Number transferred:

141

2OO

Transfer #3

44 embryos

#108

10:28
Transfer #1

50 embryos

#114
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TABLE 5-continued

Fibrinogen Porcine Embryo Data
Transfer Totals

Expt. 1
Transfers:

3

Expt. 2 Oct. 25, 1993
4

Transfer #2

50 embryos
Embryos Transfer:

47

50

32.6

35.3

31.2

10

i140

Transfer #4

50 embryos
Embryos Pig:

#139

Transfer #3

50 embryos
Ovulations/Pig:

ID

#131

37

All embryos were injected with the three fibrinogen con
structs at a total DNA concentration of 5 g/ml or about
200-300 copies of each construct per pl.
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EXAMPLE 6

Preparation of Milk and Whey from Transgenic

to each well, and the mixtures incubated at 37° C. for 45

Animals

Lactating mice were milked once on about day 12 of lac
tation. The mice were first separated from their young for
approximately 5 hours. They were then anesthetized with 0.4
ml avertin at 2.5% (im.), and 0.2 ml oxytocin was then admin
istered at 2.5 IU/ml (i.p.) to permit release of the milk. A
milking device consisting of a vacuum pump (2.5 psi) and
Syringe with an Eppendorf tip was used to direct milk into an
eppendorf tube. As noted above, milk should not be placed on
ice because of cryoprecipitation of fibrinogen.
To prepare whey, milk was diluted 1:1 with TRIS buffer
(0.03 M Tris pH 7.4; 0.06 M NaCl) and centrifuged in a
TLA-100 rotor in a Beckman TL-100 table top ultracentri
fuge at 51,000 rpm (89.000xg) for 30 minutes at room tem
perature. After centrifugation, the whey (infranatant fluid)
was collected with an 18 gauge needle, leaving the casein
pellet and upper cream layer in the tube. To remove solids or
cream that co-transferred during the initial recovery, the whey
obtained from the first centrifugation was subjected to a sec
ond spin at 12,000 rpm for 30 minutes in a TMA-4 rotor in a
Tomy MTX-150 centrifuge. Following the second spin, the
whey was recovered as before.

minutes. The wells were washed and blocked as above for 10
25

30

35

40

Table 6 presents the results of the analyses of rhFIB by the
P/M ELISA system described above in the first lactation
whey (and in whole milk by calculation) of three founder (Fo)
transgenic mice whose genome contained each of the AC, Bf3,
and GY chains cloNAs for human fibrinogen. In this experi
ment, “whey refers to skim milk diluted 1.7x with EDTA to
solubilize the caseins. The averages of four dilutions of each
whey sample for the three test animals was about 16.3, 3.86
and 7.55 ug/ml, respectively. The corresponding values for
whole milk were 27.6, 6.56 and 12.8. Second lactation pro
duction of rhEIB was similar.

45

In another experiment with the same animals the first lac
tation whey fibrinogen concentrations averaged about 22-4
(animal 1), 9+2 (animal 22) and 11+3 (animal 23) ug/ml. The
second lactation of animal 1 produced 17t3 ug/ml whey.
The P/M ELISA system was used to assay for rhFIB in the
third lactation milk of mouse no. 1/Fo and the first lactation of

50

A sandwich ELISA was used to measure the amount of FIB

55

whole milk.

Generally, in the first step of the P/M ELISA system, a
fibrinogen or fibrinogen chain analyte-containing sample (for
example, whey) is incubated with a mouse anti-human
fibrinogen mAb (clonal number 311, American Diagnostics)
that is reactive with the alpha chain of fibrinogen to form a
mAb-fibrinogen (or chain) first complex. This first complex is
then “captured by incubation with rabbit polyclonal anti
human fibrinogen antibodies immobilized in microliter plate
wells. In the detection step, the captured fibrinogen (or alpha
chains) is contacted with labeled (horse radish peroxidase)
anti-mouse IgG, and the amount of label quantified by reac

45 minutes. After washing the wells as above, 100 ul of
o-phenylenediamine solution (1 tablet/5 ml diluent) were
added to each well. After waiting about 2-3 minutes for color
development, reactions were stopped by the addition to each

well of 100 ul of 3 NHSO. Plates were then read at 490 nm.

Determination of Fibrinogen in Milk by a Sandwich
protein produced by founder and progenic transgenic animals
in the diluted skim or defatted milk (here termed “whey'); the
whey value is used to estimate the concentration of FIB in

minutes at room temperature. 100 ul of 1:1000 diluted horse
radish peroxide-conjugated rabbit anti-human FIB were
added to each well, and the mixtures incubated at 37° C. for

EXAMPLE 7
ELISA

20
tion with o-phenylenediamine and measurement of absor
bency at 490 nmi; this is a measure of the amount of analyte
present. Standard curves were obtained by spiking the whey
of control (nontransgenic) animals with pure reference
human FIB material. Thus, the presence of background
amounts of FIB is normalized by the standard curve. This
sandwich ELISA gives very low background values (about
0.06 absorbency units at 490 nm) for mouse whey alone with
no human FIB. Note the typical signals given in Table 6 are
about 0.25 or higher absorbency units at this wavelength.
In the P/P system, Immulon II 96-well microliter plates
were coated with 100 pul?well of 1:500 diluted rabbit anti
human FIB (Celsus cat. no. 60960) in 0.1 M NaHCO-0.1 M
NaCl, pH 9.6, for 24 hours at refrigerator temperatures.
Coated wells were washed three times with Wash Buffer (25
mM Tris-HC1-50 mM. NaCl-0.5% Tween-20, pH 7.0) and
blocked for 20 minutes with Dilution Buffer (1 mg/ml PEG in
25 mM Tris-HC1-50 mMNaCl, pH 7.0) at room temperature.
A volume of 100 ul of standard human FIB (100 ng/ml to 1.9
ng/ml range) and/or 100 ul of diluted milk sample was added

60

65

mouse no. 1 female offspring (1-11/F1). As shown in the data
of Table 7, mouse no. 1/Fo had about 71 ug/ml, and her
offspring (no. 1-1 1/F1) had about 53 g/ml total FIB signal.
Thus, the amount of rFIB after subtracting background is
calculated to be about 50 ug/ml for mouse no. 1/Fo and about
32 ug/ml for offspring 1-1 1/F1, respectively, over that of
endogenous FIB present from serum to milk passover. The
slightly lower value (28 ug/ml) of the P/Massay of the pre
vious lactation of mouse no. 1/Fo is not significantly different
than the P/P value when lower detection sensitivity of the
former method is taken into account. It is noted that collection

of mouse milk is inherently traumatic and, leads to serum
passover of endogenous mFIB.
In summary, mouse no. 1/Fo (founder) produced rEIB in
milkata level of about 30 ug/ml or greater over 3 lactations as
detected by either the P/M or P/P ELISA methods, and has
passed this trait on into the F1 generation which, in mouse no.
1-1 1/F1, produced 32 g/ml rFIB.

US 7,435,869 B2
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TABLE 7

Inheritability of Transgenic rhEIB Gene
Mouse No.
1 Fo
1-11 F1

Control whey

diluted whey

grhFIB/ml milk

14.O 2.0
10.4 0.8

71.O
53.0

4.O. O.7

21.O
10

These productions are Substantially greater than the 2
ug/ml produced in the COS1 system described by Roy et al.,

22
Nitrocellulose papers (40 microns pore size) were purchased
from Sigma Chemical Company. DEAE-Fast flow sepharose
was purchased from Pharmacia Biotech (Piscataway, N.J.).
DEAE chromatography was performed with Pharmacia C-10
columns (15 cmx1 cm), a Masterflex peristaltic pump, a
Knauer spectrophotometer, and a Rainin data acquisition sys
tem were used to monitor chromatography. All other reagents
were purchased from Sigma Chemical Company at the best
grade available. Columns were kept at 4°C. with a Lauda
Super RMT water cooler.
A. Separation of Transgenic Human FIB from Host Mouse
FIB

1991, above.
A sequence of anion exchange adsorption to reduce back
Western analysis of control mouse milk using polyclonal 15 ground protein content followed by a 2-step Zinc ion-selective

anti-human fibrinogen antibody showed about 21 ug/ml of
background fibrinogen signal (see Table 7). Western analysis
that uses the clonal number 311 or Y18 monoclonal antibody
has a lower limit of sensitivity of about 1 ul sample of 100
ug/ml fibrinogen (Phastgel system) or 20 Jul of 25 g/ml in a
3" by 4" SDS-PAGE gel.

separation of hFIB or rhFIB from mouse FIB was done on
mouse milk whey and mouse plasma samples (FIG. 8). Milk
from transgenic and non-injected control mice were diluted
with an equal volume of 200 mM EDTA, pH 7.0. An aliquot
of milk from control (nontransgenic mice) was spiked with
known hFIB to give a final concentration of 30-50 ug/ml, and

TABLE 6

1

A.

B

C
AVGABS

E

WHEY

Animal

Dilutions

490 mm

D

FIBug?ml

AVG FIBug?ml

100
2OO
400
800

O.623
O.S23
O434
O.334

O.132
O.088
0.049
0.018

13.2
17.6
19.4
14.7

1OO
2OO
400
800

O.374
O.335
O.273
O.251

O.O22
0.018,
0.014
O.O13

2.16
3.69
S.73
10.3

1OO
2OO
400
800

O.477
O.384
O.338
O.261

0.067
O.O26
0.019
O.O13

6.75
S.22
7.44
10.8

2 #1 DAY 6
3
4
5
6
7
H22
8
9
10
11
12
#23
13
14
15

16.3

27.6

3.86

6.56

7.55

12.8

EXAMPLE 8

Confirmation that Transgenic Fibrinogen is Actually
Recombinant Human Fibrinogen
Materials Used to Analyze Fibrinogen
Rabbit antisera against human fibrinogen was purchased
from Celsus laboratories (Cincinnati, Ohio). Rabbit antisera
against human fibrinogen conjugated to horseradish peroxi
dase (HRP) was purchased from Dako corporation (Carpen
teria, Calif.). Anti-rabbit immunoglobulins conjugated to
HRP were purchased from Sigma Chemical Company
(St.Louis, Mo.). Synthetic human fibrinopeptide A was pur
chased from Sigma Chemical Company. Rabbit antisera
against human fibrinopeptide A was purchased from Nordic
Immunological Laboratories (Caplstrano Beach, Calif.).
Immulon II microtiter plates were purchased from Fisher
Scientific (Pittsburgh, Pa.). Plasma derived human fibrinogen
was provided by American Red Cross. (Rockville, Md.).
O-phenylenediamine-2HCl (OPD) tablets were purchased
from Abbott Laboratories (Chicago, Ill.). Metal enhanced
DAB substrate was purchased from Pierce Chemical Com
pany (Rockford, Ill.). Centricon diafilters were purchased
from Amicon (Bedford, Mass.). 4-15% gradient phast-gels
were purchased from Pharmacia Biotech (Piscataway, N.J.).

45

50

55

60
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diluted with 1 part EDTA. The milk: EDTA mixture was cen
trifuged at 4400 rpm for 45 minutes and the whey phase was
separated from the top fat layer. Mouse blood was used as a
positive control to measure cross-reactivity of anti-human
fibrinogen antisera to mouse fibrinogen. All samples were
diafiltered against TBS (25 mM Tris-HCl, 100 mM. NaCl, pH
7.0) and then were fractionated on a DEAE Fast Flow
Sepharose packed column at a linear Velocity of 1 cm/min.
The column dimensions were: 1 cm bed diameter and 6 cm in

length. A fraction obtained by elution with 0.2 MNaCl frac
tion was diafiltered against TBS and reconstituted to the
original sample Volume. Using a 0.5 MZnCl2 stock solution,
the Zinc ion concentration in the samples was adjusted to 10
mM. This gave a visible precipitate which was separated by
centrifugation at 10000 rpm (rotor diameter 6 inches) for 20
mins (pellet 1). Pellet-1 was dissolved in 100 mM EDTA, pH
7.0. Using the stock Solution, the Zinc concentration in the
supernatant fluid was adjusted to 24 mM. The resultant pre
cipitate was centrifuged at 10000 rpm for 10 mins and the
sediment (pellet-2) was dissolved in 100 mM EDTA, pH 7.0.
EDTA solutions from pellet-1 and pellet-2, as well as associ
ated-supernatant fluids, were analyzed for rhFIB by ELISA
and the fractions were diafiltered against TBS.
Pellets from control mouse whey alone (no doped human
fibrinogen) were dissolved to the same dilution factor as
pellets from transgenic whey and human fibrinogen doped
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control whey. ELISA values for the dissolved transgenic hFIB (lanes 5-8), but a higher molecular weight than mouse
whey and human fibrinogen doped control whey were 30-50 fibrinogen. The C.B chains of rhFIB show up with greater
ug/ml human fibrinogen. The control (pellet-2) when recon intensity than the Y chain.
stituted to the same volume as TG (pellet-2) or hFIB spiked D. Thrombin Assay
control whey (pellet-2) gave a fibrinogen level of 1-2 g/ml as 5 Diafiltered rhEIB-rich fractions from the zinc selective
measured by ELISA.
The pellet-2 of non-transgenic whey was also reconstituted separation steps were suspended in 50 mM imidazole, 150
to a 20-fold more-concentrated level than transgenic whey mM NaCl, 30 mM CaCl, pH 8.0. Human thrombin was
to a final concentration of 4U/ml and the samples were
and human fibrinogen doped control whey. This 20-fold con added
incubated at 37°C. for 24 hours. Cloudy clot-like precipitates
centrated, negative control was assayed by ELISA, and the 10 were
visible in TG (pellet-2), hFIB-spiked NTG (pel
value was then 30 g/ml human fibrinogen cross reactive let-2),clearly
but
not
in control whey (pellet-2) after treated with
equivalent signal with human fibrinogen antisera.
The dissolved pellets from transgenic whey and human thrombin. The clots were boiled for 3 mins and centrifuged at
10000 rpm for 10 minutes. The clot pellets were dissolved in
fibrinogen doped control whey having 30-50 ug/ml human reducing
cocktail buffer. Assay Supernatant was lyophilized
fibrinogen by ELISA signal were applied to a phast-gel, SDS- 15
and
reconstituted
to /1oth the initial reaction volume. Super
PAGE (1 Jul sample Volume applied to phastgel). A 1 Jul appli
natant was assayed for any residual fibrinogen and/or fibrin
cation of the 20 fold-more concentrated, negative-control, by
ELISA. The level of FPA in the concentrated supernatants
dissolved pellet also was applied to the gel.
were determined by EIA technique.
B. Western Blot Analysis Under Non-Reducing Conditions
Western Blot Analysis. After Treatment of FIBs with
hFIB (reference) in assay buffer, diafiltered mouse plasma E.
Human
Thrombin
and rhFIB- rich fraction (pellet-2 of zinc separation step) of
Samples were taken before the addition of thrombin
transgenic whey were mixed with non-reducing cocktail at
4:1 ratio and boiled for 5 minutes. Samples were analyzed on (Time=0 mins) and the clot after polymerization were dis
a 4-15% SDS-phast gel. Upon the completion of electro 25 solved in reducing buffer. Samples were analyzed on a 8-25%
gel in the presence of SDS. The results are shown in
phoretic separation, the proteins were blotted onto a nitrocel phast
lulose membrane via “phast-gel diffusion blotting.” The blot FIG 11.
Lanes 1 and 2 of FIG. 11 show human fibrinogen reference
was probed for hFIB or rhFIB by a sandwich of rabbit anti
human fibrinogen antibody and anti-rabbit HRP conjugate protein in buffer at concentrations of 50 and 10 ngs before the
antibody. Bound chromophore was visualized by metal 30 addition of thrombin. Lane 3 shows the dissolved clot gener
ated from hFIB at an initial concentration of 10 ng. Lane 4
enhanced DAB substrate. The results are shown in FIG. 9.
shows trangenic whey pellet-2 FIB (30 ng applied to gel)
Lanes 1 and 8 of FIG. 9 show applications of hFIB refer before
addition of thrombin. Lane 5 shows dissolved clot
ence protein at 100 and 10 ngs. Lanes 2 and 3 shows the
generated
from transgenic whey pellet-2 FIB. Lane 6 shows
transgenic pellet from mouse (1-11-8) at 15 ngs. Lanes 4 and
show the transgenic pellet from mouse 1-6-8 at 30 ngs. Lane 35 mouse plasma derivative (30ng total FIB cross reactive signal
6 shows mouse plasma derivative at 2-4 ug of total protein by ELISA, 1000 ng mouse FIB by silver-stain analysis using
SDS-PAGE). Lane 7 shows samples from the incubation of
application. Lane 8 shows pellet-2 from control whey.
The mobilities of rhFIBs under non-reducing conditions on mouse plasma derivative FIB with thrombin; this precipitate
4-15% PAGE phast-gel from two different transgenic mice is not the cloudy gel-like precipitate seen with TG whey
lines are similar to that of the plasma-derived hFIB reference 40 (pellet-2) and hFIB spiked control whey (pellet-2).
The Western analysis under reducing conditions of the
(lanes 2-5). Intact mouse FIB from plasma (lane 6) and con
trol whey pellet-2 (lane 7) migrated as multiple bands with a hFIB reference protein shows three distinct chains, and the
distinctly apparent higher molecular weight as compared to dissolved clot resulting from thrombindigestion shows three
chains with an apparent lower molecular mobility under
human FIB (lanes 1 and 10).
reduced conditions. Release of fibrinopeptide A from the a
45
C. Western Blot Analysis Under Reducing Conditions
chain by incubation with thrombin results in a lower apparent
hFIB (reference protein) in assay buffer, diafiltered mouse molecular of the a chain. Dissolved clots from transgenic
plasma and rhFIB-rich fraction (pellet-2 of zinc separation whey (pellet-2) under reducing conditions gave two distinct
step) of transgenic whey were mixed with reducing cocktail at bands with lower apparent molecular weights when com
4:1 ratio and boiled for 5 minutes. Samples were analyzed on pared to rhFIB before addition of thrombin. A mouse plasma
a 8-25% SDS-phast gel. Upon the completion of electro 50 sample gave bands which were reactive to FIB antisera and
phoretic separation, the proteins were blotted onto a nitrocel had lower apparent molecular weights than reduced hFIB.
lulose membrane via “phast-gel diffusion blotting.” The blot
was probed for hFIB or rhFIB by a sandwich of rabbit anti F. Assay of Fibrinopeptide A After Thrombin Digestion of
human FIB and anti-rabbit HRP conjugate antibodies. Bound rhEIB
chromophore was visualized by metal-enhanced DAB sub 55 The levels of FPA in the concentrated samples were deter
strate. The results are shown in FIG. 10.
mined by an EIA technique. Immobilon AV membranes were
Lanes 1, 2 and 3 of FIG. 10 show applications of hFIB wetted in imidazole buffer for 10 minutes and dried for 60-90
reference at 100, 50-and 10 ngs. Lane 4 shows mouse plasma minutes at room temperature. FPA standards ranging from
derivative (i.e. diafiltered 0.2. MNaCl eluate from DEAE FF 0.2-0.125 mg/ml and assay Supernatant fluids were applied as
Sepharose column). Lane 5, 6, 7 and 8 show applications of 60 1 ul spots onto a pre-wetted Immobilon AV membrane for the
transgenic whey pellet-2 at 60, 30, 15 and 7.5 ngs.
purpose of covalent immobilization. Smaller peptides such as
Under reduced conditions, C, B and Y chains of reference FPA (MW 1,800) are kinetically favored for immobilization
hFIB from human plasma are clearly visible (lanes 1-3). over larger peptides or milk proteins with molecular weights
Fibrinogen chains from mouse plasma (lane 4) have lower in excess of 10,000. The spots were allowed to dry at room
apparent molecular weights than human FIB, but different 65 temperature and the membrane was blocked with 0.5% casein
than rhEIB. Partially purified material from transgenic whey for 2 hours at the same temperature. Covalently bound FPA
has three chains with lower apparent molecular weights than was detected with a sandwich of rabbit anti-FPA and anti
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rabbit/HRP conjugate antibodies. Bound chromophore was
detected with metal enhanced DAB substrate. The spots were
scanned on a Shimazdu Densitometer at 270 nm. The results
are summarized in Table 8.

FPA standards ranging from 200-6.25 ngs were applied to
enzyme immunoassay (EIA) membranes for reference signal
curves. Transgenic whey derivatives that had been selectively
enriched for recombinant human fibrinogen by precipitation,
were similarly applied and analyzed for the release of FPA
before and after human thrombin treatment for 24 hours.

Analogously prepared and then thrombin treated, non-trans
genic whey derivatives were also compared in the same EIA
assay. These results are summarized in Table 8 entitled
“Thrombin treatment of Fibrinogen Samples'.
The yield of FPA from hFIB in assay buffer treated with
thrombin was 100+10% based on three independent trials
(Table 8). No detectable amount of FPA was released from
control whey (pellet-2) treated with thrombin. 1,000 ng of
mouse FIB from mouse plasma (equivalent to 25 ngs of FIB
cross reactive signal) gave a FPA yield of 5%. Transgenic
whey (pellet-2) and hFIB spiked control whey (pellet-2)
when treated with thrombin released FPA in the supernatant

10

15

Zn+ selective purification scheme. Zn4 is a coordinate

25

% FPA
yield
35

Sample

T=O

T = 24

T = 24

(Supernatant)

min

hours

hours

hFIB (buffer)
hFIB (buffer)
Spiked NTG whey

100
10
50

O.1
n.d.
O.1

1OO 5
1OO 10
7S 9

30
30
30

n.d.
n.d.
n.d.

608
n.d.
5

(pellet-2)
TG whey (pellet-2)
NTG whey (pellet-2)
Mouse plasma

Changes intertiary confirmation by Zn-bonding are reflected
in a Zn-concentration dependent manner by the precipitation
(loss of solubility). Similar amounts of recombinant and

human FIB precipitated out at 24 mM Zn4 and as found in

Thrombin Treatment of Fibrinogen Samples
Fibrinogen giml
ELISA

covalent bonder of proteins primarily through access to proxi
mally portioned, Surface positioned histidine residues, and
thus the tertiary conformation of the proteins is changed by

the formation of Zn-i- bonds Lonnerdal (1982), supra.
30

TABLE 8

addition of human thrombin. A normal fibrin clot and sto

ichiometric release of FPA into the supernatant solution was
found after treatment with thrombin. A characteristically
lower apparent molecular weight of the fibrin chains from the
clot was found relative to the starting FIB precursor chains.
The assembled rhFIB possessed an apparent molecular
weight similar to that of human FIB reference standard. The
physicochemical properties of the rhFIB were similar to those
of hFIB as reflected by the similar partitioning during the

fluid, and no residual rhEIB or hEIB was detected in the

supernatant fluid by ELISA. The yield based on the amount of
FPA released from TG whey (pellet-2) and hEIB spiked con
trol whey (pellet-2) is estimated to be 60+8% and 75+9%.
respectively based on three independent trials. A 1/1 molar
ratio of FPA to fibrinogen is assumed in the calculation.
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may have been produced by treatment with thrombin under
conditions of about 20-fold higher initial concentration of
FIB substrate than used for human FIB-doped whey deriva
tive or rhFIB samples. Both the absence of FPA and an obvi
ous clot after treatment with human thrombin was expected.
While mouse FIBundoubtedly has regions of well-conserved
sequence homology, both the mouse FPA sequence and the
nature of the digestion by human thrombin (slower reaction
kinetics due to site specificity of human thrombin for human
fibrinogen) is likely to be different. The 40-fold lower cross
reactivity of mouse FIB with anti-hFIB antisera is additional
evidence of the differences in mouse and human fibrinogens.
The FIB doped into whey and recovered by the above
purification process was readily converted to fibrin by the

human and recombinant FIB, but much different for mouse
40

45

G. Summary
Mouse FIB was found to have a higher apparent molecular
weight under nonreducing conditions both by silver-stained
SDS-PAGE gels and corresponding Western blot analyses
using polyclonal anti-human fibrinogen antisera, than human
FIB. In contrast, the separate C, B and Y chains of the mouse
plasma FIB, as detected by gel analyses under reducing con
ditions, had slightly lower apparent molecular weights (about
1-5 kDa per chain) than human FIB. These data from reduced
and nonreduced analyses indicate that the disulfide bridging
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mouse FIB is different than for the human counterpart. Fur
thermore, the cross-reactivity to anti-human fibrinogen signal
was about 40-fold less than human or rhEIB in both ELISA

FPA formation after treatment with human thrombin. But

lower apparent molecular weight FIB chain reaction products

FIB. The separate chains of rhFIB will slightly lower apparent
molecular weights than non-recombinant human FIB due
possibly to glycosylation off and Y chains. The reactivity to
anti-human fibrinogen antisera of purified recombinant
fibrinogen was generally equivalent to human fibrinogen.
The rhEIB recovered from the transgenic was readily con
verted to fibrin by the addition of human thrombin and in a
manner similar to that of human FIB reference protein. A
normal human fibrin clot and stoichiometric release of FPA

and resultant SDS-sensitive conformation of the assembled

and Western analysis assuming about 2 g/l mouse FIB in
mouse plasma reference as detected by silver stain gel. Mouse
plasma FIB was, also found in transgenic and control mouse
milks at about 200 to 300 g/ml. After purification process
ing, all Zn-derived pellet-2 from nondoped control whey or
mouse, plasmas exhibited no detectable clot formation nor

pellet-2. The sensitivity of this technique is seen with the
structurally related mouse FIB which did not precipitate to
any significant degree at this same level of Zn. Thus, the
presentation of surface histidine residues is similar between

60

65

into the supernatant solution was found after treatment with
human thrombin. The yield of FPA detected by EIA after
treatment with human thrombin for rhFIB fibrinogen was
equivalent to that obtained with human FIB. As the yields of
fibrin from human or recombinant fibrinogens were high, the
residual milk proteins present after purification did not inter
fere significantly with the thrombin-fibrinogen reaction. A
characteristically lower apparent molecular weight of the
recombinant human fibrin chains from the clot was found

relative to the starting FIB precursor chains.
In summary, these analyses have shown that the rhFIB
made has a genuine and native structure with respect to bio
logical activity. This was evidenced by its simultaneous con
Sumption and conversion into a normal fibrin clot while act
ing as a substrate during enzymatic reaction with human
thrombin, stoichiometric release of native fibrinopeptide A
upon formation of fibrin, lower relative molecular weights of
resultant fibrin polypeptide chains relative to FIB precursors,
its coordinate chemical bonding properties with Zn, and its
equivalent reactivity with human antisera relative to a human
FIB reference protein.
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SEQUENCE LISTING

<16O

NUMBER OF SEO ID NOS : 12

<210

SEQ ID NO 1

<211 LENGTH: 2O
&212> TYPE: DNA

<213> ORGANISM: Artificial Sequence
&220s FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer
<4 OO

SEQUENCE: 1

CCCC agctgc agc catgaag
<210

SEQ ID NO 2

<211 LENGTH: 28
&212> TYPE: DNA

<213> ORGANISM: Artificial Sequence
&220s FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer
<4 OO

SEQUENCE: 2

CCCC agggat at CCCtgcag C catgaag
<210

28

SEQ ID NO 3

<211 LENGTH: 30
&212> TYPE: DNA

<213> ORGANISM: Artificial Sequence
&220s FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer
<4 OO

SEQUENCE: 3

gctagg tacc atgtttitcca taggat.cgt
<210

3O

SEQ ID NO 4

<211 LENGTH: 30
&212> TYPE: DNA

<213> ORGANISM: Artificial Sequence
&220s FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer
<4 OO

SEQUENCE: 4

Cagtgg tacc ctagacaggg Cagatttag
<210

3O

SEQ ID NO 5

<211 LENGTH: 30
&212> TYPE: DNA

<213> ORGANISM: Artificial Sequence
&220s FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer
<4 OO

SEQUENCE: 5

gctagg tacc atgaaaagaa tigtttcgtg
<210

SEQ ID NO 6

<211 LENGTH: 30
&212> TYPE: DNA

<213> ORGANISM: Artificial Sequence
&220s FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer
<4 OO

SEQUENCE: 6

3O
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30
- Continued

Cagtgg tacc ctattgctgt gggaagaagg
<210

3O

SEQ ID NO 7

<211 LENGTH: 30
&212> TYPE: DNA

<213> ORGANISM: Artificial Sequence
&220s FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer
<4 OO

SEQUENCE: 7

gctagg tacc atgagttggit CCttgcaccc
<210

3O

SEQ ID NO 8

<211 LENGTH: 30
&212> TYPE: DNA

<213> ORGANISM: Artificial Sequence
&220s FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer
<4 OO

SEQUENCE: 8

cagtgg tacc ttaaacgt.ct c cagoctdtt
<210

3O

SEQ ID NO 9

<211 LENGTH: 25
&212> TYPE: DNA

<213> ORGANISM: Artificial Sequence
&220s FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer
<4 OO

SEQUENCE: 9

Ctgtgtggcc aagaaggaag tittg
<210

25

SEQ ID NO 10

<211 LENGTH: 24
&212> TYPE: DNA

<213> ORGANISM: Artificial Sequence
&220s FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer
<4 OO

SEQUENCE: 10

gatgtc.tttc. cacaac cctt gggc
<210

24

SEQ ID NO 11

<211 LENGTH: 23
&212> TYPE: DNA

<213> ORGANISM: Artificial Sequence
&220s FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer
<4 OO

SEQUENCE: 11

cc.cgatagcc acct cotctg atg
<210

SEQ ID NO 12

<211 LENGTH: 24
&212> TYPE: DNA

<213> ORGANISM: Artificial Sequence
&220s FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

23
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32
- Continued

<4 OO

SEQUENCE: 12

Cctggactitc aaagtagcag cqtc

24

What is claimed is:

1. A method for producing biologically active fibrin com
prising:
providing a transgenic non-human mammal whose
genome comprises a first DNA segment encoding a het
erologous fibrinogen AC chain, a second DNA segment
encoding a heterologous fibrinogen Bf3 chain, and a third
DNA segment encoding a heterologous fibrinogen Gy
chain, wherein each of said first, second and third seg
ments is operably linked to a cis-acting, expression pro
moter-containing regulatory sequence;
allowing the expression of said first, second and third DNA
segments in said mammal and the production of milk
containing said biologically active fibrinogen;
collecting milk from said mammal;
recovering the fibrinogen from said milk, and
converting the fibrinogen to fibrin by reacting the fibrino
gen with thrombin.

10

7. The method of claim 6, wherein said conversion of
15

25

2. The method of claim 1, wherein said conversion of

fibrinogen to fibrin occurs in a Subject which has been admin
istered said fibrinogen.
3. A method for producing biologically active fibrin com
prising:
providing a transgenic non-human mammal whose
genome comprises a first DNA segment encoding a het
erologous fibrinogen AC chain, a second DNA segment
encoding a heterologous fibrinogen Bf3 chain, and a third
DNA segment encoding a heterologous fibrinogen Gy
chain, wherein each of said first, second and third seg
ments is operably linked to a cis-acting, expression pro
moter-containing regulatory sequence;
allowing the expression of said first, second and third DNA
segments in said mammal and the production of milk
containing biologically active fibrinogen;
collecting milk from said mammal;
recovering the fibrinogen from said milk, and
converting the fibrinogen to fibrin by reacting the fibrino
gen with at least one protease.
4. The method of claim 3, wherein said conversion of

fibrinogen to fibrin occurs in a Subject which has been admin
istered said fibrinogen.
5. A method for producing biologically active fibrin com
prising:
recovering fibrinogen from the milk of a transgenic non
human mammal whose genome comprises a first DNA
segment encoding a heterologous fibrinogenAC chain, a
second DNA segment encoding a heterologous fibrino
gen Bf3 chain, and a third DNA segment encoding a
heterologous fibrinogen GY chain, wherein each of said
first, second and third segments is operably linked to a
cis-acting, expression promoter-containing regulatory
sequence which allows the expression of said first, sec
ond and third DNA segments in said mammal; and
converting the fibrinogen to fibrin by reacting the fibrino
gen with at least one protease.

6. The method of claim 5, wherein said protease is throm
bin.
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fibrinogen to fibrin occurs in a Subject which has been admin
istered said fibrinogen.
8. A method for producing biologically active fibrinogen
comprising:
providing a female transgenic non-human mammal com
prising stably integrated in its genome a first DNA seg
ment encoding a first DNA segment encoding a heter
ologous fibrinogen AC chain, a second DNA segment
encoding a second DNA encoding a heterologous
fibrinogen Bf3 chain, and a third DNA segment encoding
a third DNA encoding a heterologous fibrinogen Gy
chain, wherein each chain is derived from the same

species, and wherein each of said first, second and third
segments is operably linked to a promoter-containing
regulatory sequence required for its expression in a
mammary gland of a transgenic non-human mammal;
allowing the expression of said first, second and third DNA
segments and the assembly of the expressed individual
AC, BB and GY polypeptides into biologically active
fibrinogen in the cells of the mammary gland followed
by the secretion of the biologically active fibrinogen into
the milk of said female mammal;

collecting milk from said mammal; and
recovering the biologically active fibrinogen from the milk
in concentrations of 30 ug/ml or greater.
9. The method according to claim 8, wherein said trans
genic non-human mammal is selected from the group con
sisting of a rodent, rabbit, sheep, pig, goat and cattle.
10. The method according to claim 8, wherein said pro
moter is a mammary gland specific promoter.
11. The method according to claim 10, wherein said pro
moter is selected from the group consisting of casein, 3-lac
toglobulin, C.-lactalbumin and whey acidic protein gene pro
moters.
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12. The method according to claim8, wherein said fibrino
gen is human fibrinogen.
13. The method according to claim 8, wherein said first,
second, and third DNA segments further comprises an intron.
14. A method for producing biologically active fibrinogen
comprising:
providing a first DNA segment encoding a heterologous
fibrinogen AC chain, a second DNA segment encoding a
heterologous fibrinogen Bf3 chain; and a third DNA seg
ment encoding a heterologous fibrinogen GY chain,
wherein each chain is from the same species, and
wherein each of said first, second and third segments is
operably linked to a promoter-containing regulatory
sequence required for its expression in the mammary
gland of a female transgenic non-human mammal;
introducing said DNA segments into a fertilized egg of a
non-human mammalian species heterologous to the spe
cies of origin of said fibrinogen chains;
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inserting said egg into an Oviduct or uterus of a female of
said mammalian species to obtain a transgenic non
human mammal whose genome comprises said DNA

34
22. The method according to claim 20, wherein said pro
moter is a mammary gland specific promoter.
23. The non-human transgenic mammal according to claim
22, wherein said promoter is selected from the group consist
ing of casein, B-lactoglobulin, C.-lactalbuminand whey acidic
protein gene promoters.
24. The non-human mammal according to claim 20,

Segments;

breeding said mammal to produce female progeny that
express said first, second and third DNA segments,
wherein the assembly of the expressed individual AC.
BB and Gypolypeptides into biologically active fibrino
gen occurs in the cells of the mammary gland followed
by the secretion of the biologically active fibrinogen into

wherein said mammal is female.
10

collecting milk from said female progeny; and
recovering the biologically active fibrinogen from the milk
in concentrations of 30 ug/ml or greater.
15. The method according to claim 14, wherein said trans
genic non-human mammal is selected from the group con
sisting of a rodent, rabbit, sheep, pig, goat and cattle.
16. The method according to claim 14, wherein said first,
second, and third DNA segments further comprises an intron.
17. The method according to claim 14, wherein said pro
moter is a mammary gland specific promoter.
18. The method according to claim 17, wherein said pro
moter is selected from the group consisting of casein, 3-lac
toglobulin, C.-lactalbumin and whey acidic protein gene pro

15

moters.
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19. The method according to claim 14, wherein said
fibrinogen is human fibrinogen.
20. A transgenic non-human mammal, wherein the genome
of said mammal comprises:
a first DNA segment encoding a heterologous fibrinogen

30

AC. chain;

a second DNA segment encoding a heterologous fibrino
gen Bf3 chain; and
a third DNA segment encoding a heterologous fibrinogen
GY chain; and
wherein each chain is derived from the same species and is
operably linked to a promoter-containing regulatory
sequence required for its expression in the mammary
gland of a host mammal, and wherein expression of said
DNA segments and the assembly of the expressed indi
vidual AC, BB and Gy polypeptides into biologically
active fibrinogen occurs in the cells of the mammary
gland followed by the secretion of the biologically active
fibrinogen into the milk, if said mammal is female,
resulting in the production of recoverable quantities of
biologically active fibrinogen from milk of said non
human mammal in concentrations of 30 ug/ml or greater.
21. The non-human transgenic mammal according to claim
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cattle.

26. The method according to claim 20, wherein said first,
second, and third DNA segments further comprises an intron.
27. The method according to claim 20, wherein said
fibrinogen is human fibrinogen.
28. A process for producing a transgenic non-human mam
mal comprising:
providing a first DNA segment encoding a first DNA
encoding a heterologous fibrinogen AC chain, a second
DNA segment encoding a second DNA encoding a het
erologous fibrinogen Bf3 chain, and a third DNA seg
ment encoding a third DNA encoding a heterologous
fibrinogen Gy chain, wherein each chain is derived from
the same species, and wherein each of said first, second
and third segments is operably linked to a promoter
containing regulatory sequence required for its expres
sion in a mammary gland of a host female mammal;
introducing said DNA segments into a fertilized egg of a
non-human species heterologous to the species of origin
of said fibrinogen chains;
inserting said fertilized egg into an Oviduct or uterus of a
female of said mammalian species; and
allowing said fertilized egg to develop thereby producing a
transgenic non-human mammal whose genome com
prises said first, second and third DNA segments, which
are expressed as individual AC, Bf3 and GY polypeptides
that are assembled into biologically active fibrinogen in
the cells of the mammary gland followed by the secre
tion of the biologically active fibrinogen into the milk, if
said mammal is a female progeny, resulting in the pro
duction of recoverable quantities of biologically active
fibrinogen from milk of said female progeny in concen
trations of 30 g/ml or greater.
29. The process according to claim 28, wherein said mam
mal is female.

30. The process according to claim 28, wherein said mam
mal is male.

20, wherein said non-human mammal is selected from the

group consisting of a rodent, rabbit, sheep, pig, goat and

25. The non-human mammal according to claim 20,
wherein said mammal is male.

the milk of said female mammal;
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